Roche Launches Legal Battle Against Biogen’s Imitative Biosimilar of Blockbuster Arthritis Drug July 14, 2023 – Roche (ROG.S) and its subsidiary powerhouses have taken a decisive step by initiating legal proceedings against biotech frontrunner Biogen (BIIB.O) in the federal court of Massachusetts. Their grievance centers around Biogen’s audacious attempt to replicate Roche’s highly successful drug…
Introduction The field of generative artificial intelligence has seen remarkable advancements in recent years, enabling machines to create images and generate text. However, its potential goes far beyond art and literature. Absci Corporation, a pioneering company in antibody therapeutics, is leveraging generative AI to revolutionize drug discovery. By harnessing the power of machine learning, Absci can…
A Lexington-based biotech firm, Cyteir Therapeutics Inc., has declared its plan to disband a mere two years following its public debut via an IPO. The company’s announcement on Friday included intends to cease the development of its solitary drug, a clinical-stage program designed to treat ovarian and other solid-tumor cancers. Cyteir aims to liquidate its…
Roche, a leading biotechnology company, has obtained clearance from the U.S. Food and Drug Administration (FDA) for other Alzheimer’s disease Cerebrospinal Fluid (CSF) assays. The newly cleared assays, known as Elecsys tTau/Abeta42 ratio, are crucial in enabling timely diagnosis and facilitating treatment decisions for Alzheimer’s disease. The Elecsys tTau/Abeta42 ratio is designed to assist clinicians…
Introduction: In a significant development, a committee of expert advisors to the U.S. Food and Drug Administrator has endorsed for full approval of an Alzheimer’s disease drug developed by Biogen Inc. in collaboration with Eisai. The committee’s unanimous 6-0 vote concluded that Leqembi, the drug in question, demonstrated clinical benefit for patients, meeting the prerequisite…
Introduction: Parkinson’s disease is a progressive neurological disorder affecting millions worldwide. It is characterized by tremors, stiffness, and impaired movement, among other symptoms. Despite decades of research, there is currently no cure for Parkinson’s disease, and limited treatment options are available to patients. However, recent advances in biomarker research offer hope for earlier detection and…
NATICK, MASSACHUSETTS, UNITED STATES OF AMERICA, March 28, 2023/EINPresswire.com/ — NeuroDex, Inc.’s approved application, titled “Clinical Validation of a Robust Blood Test Using Neuron-Derived Exosomes for Detection of Alpha-Synuclein/TDP43 Pathologies in Patients with Alzheimer’s Disease,” highlights NeuroDex, Inc.’s unique methodology for isolation and analysis of neuron-derived exosomes.NeuroDex, Inc. (“NeuroDex”, or the “Company”), announces that it has…
Neurodegenerative diseases Neurodegenerative diseases are a complex and growing public health concern. These conditions, including Alzheimer’s disease, Parkinson’s disease, and Lewy body dementia, can cause significant disability and reduced quality of life. Unfortunately, diagnosing these diseases can be challenging, with current diagnostic methods often requiring invasive procedures, such as brain imaging or lumbar puncture. Neurodex…
For application titled: “Blood Test for Parkinson’s Stratification based on Neuron and Oligodendrocyte Derived Extracellular Vesicles”NATICK, MASSACHUSETTS, UNITED STATES OF AMERICA, January 26, 2023 /EINPresswire.com/ — NeuroDex, Inc.(“NeuroDex”, or the “Company”), announces that it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to study, “Blood Test for Parkinson’s Stratification based on Neuron…